About
Michel Revel (born 1938 in France) has M.D. and Ph.D. degrees. In 1968, he joined the Weizmann Institute of Science, Rehovot, Israel, where he has been a full Professor since 1973, heading for several periods the Departments of Virology and of Molecular Genetics. He is an emeritus Professor since 2010. Prof. Revel is best known for his work on the mechanism of action of interferon and the cloning of the genes for human interferon beta (IFN-β) and interleukin-6 (IL-6). He developed the first efficient genetic engineering production of a protein (IFN- ) in animal cells (CHO cells). He was Chief Scientist of InterPharm (Serono group), which produced the recombinant IFN- (Rebif), a leading drug for treatment of Multiple Sclerosis, now 20 years in the market and sold in 90 countries by Merck Kga. Since 2010, Prof. Revel is co-founder and Chief Scientist of Kadimastem, an Israeli company producing human tissues by differentiation of pluripotent stem cells (ESC). The first product of Kadimast
Position in the VCSift Database
- • 2 investors at Emeritus are tracked.
- • 1 investors hold the Prof. role in VCSift. Michel Revel is one of them.
- • 610 investors are based in Israel.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- Israel
Contact Information
Find more investors like Michel
Search Investors